Wallerian Degeneration
Overview
Wallerian Degeneration describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders.
Wallerian degeneration is a conserved neural process wherein the distal portion of an axon degenerates following injury to its proximal axon segment or cell body. First described by Augustus Waller in 1850, this process is fundamental to nervous system development, injury response, and has emerged as a critical pathway in understanding neurodegenerative diseases[@waller].
Historical Background
In 1850, Augustus Waller described the degeneration of frog glossopharyngeal and hypoglossal nerve fibers following transection. He observed that the portion of the axon disconnected from its cell body underwent granular disintegration while the neuron soma remained intact. This landmark observation established the principle that the neuron cell body maintains axonal integrity—a concept central to modern neuroscience[@waller].
The historical significance of Waller's discovery cannot be overstated. Prior to his work, the prevailing view held that nerve fibers degenerated as a unitary system. Waller's meticulous anatomical observations revealed that the neuron operates as a functional unit: damage to the cell body or proximal axon triggers degeneration of the entire distal segment, while the proximal portion connected to the cell body remains viable. This principle laid the foundation for our understanding of axonal biology and continues to inform modern research on neurodegeneration.
Molecular Mechanisms
The Axon Degeneration Program
Wallerian degeneration is not merely a passive process of decay but an active, genetically programmed response. The discovery of the Wallerian degeneration slow (Wld^S) mouse, which exhibits dramatically slowed axonal degeneration, identified key molecular players[@coleman2010]. This spontaneous mutation, first characterized in the 1990s, provided crucial insights into the mechanistic underpinnings of axonal destruction and revealed that the degeneration process could be pharmacologically manipulated.
The Wld^S mouse carries a chimeric gene rearrangement that fuses a portion of the ubiquitin assembly factor UBE4B with the NAD+ biosynthetic enzyme NMNAT1. This fusion protein stabilizes NAD+ levels in injured axons, dramatically slowing the degenerative process. The discovery that enhancing NAD+ biosynthesis could delay axonal death was revolutionary and spawned an entire field of research into axon-protective therapies.
SARM1: The Central Executor
Sterile alpha and TIR motif containing 1 (SARM1) is the central executioner of axonal degeneration[@osterloh2012]:
- Structure: Contains an N-terminal ARM domain, a SAM (self-association motif), and a TIR (Toll/IL-1 receptor) domain
- Activation mechanism: Upon injury, NAD+ levels drop rapidly in the distal axon. SARM1 senses this metabolic crisis and triggers a self-amplifying cycle of NAD+ depletion
- TIR domain signaling: The TIR domain functions as an NADase, directly degrading NAD+ and generating cyclic ADPR (cADPR), a second messenger that promotes calcium release from stores
- Energy collapse: The rapid NAD+ depletion causes ATP exhaustion, leading to membrane failure and axonal disintegration[@osterloh2012][@essuman2017]
The SARM1 protein exists in an auto-inhibited state in healthy axons. Under normal conditions, the TIR domain is held in an inactive conformation by the ARM domain. Injury triggers a conformational change—likely mediated by metabolic stress signals—that releases this inhibition, activating the NADase function. Once activated, SARM1 initiates a feed-forward destruction cascade: its NADase activity depletes NAD+, which further activates SARM1, creating a self-amplifying loop that rapidly destroys the axon's metabolic capacity.
The structural biology of SARM1 activation has been intensely studied. Crystal structures reveal that the auto-inhibited conformation involves extensive interactions between the ARM and TIR domains. Mutations that disrupt these interactions cause constitutive activation, while mutations that stabilize the interaction prevent activation even after injury. This has led to the development of small molecules that stabilize the auto-inhibited state—a promising therapeutic approach.
NMN and NAD+ Balance
The balance between nicotinamide mononucleotide (NMN) and NAD+ is critical[@essuman2017]:
- NMN accumulation: Injury causes NMN to accumulate due to continued synthesis by nicotinamide phosphoribosyltransferase (NAMPT)
- NAD+ synthesis inhibition: High NMN levels inhibit NAD+ synthesis, creating a feed-forward loop
- Therapeutic targeting: Inhibiting NMN synthesis or enhancing NAD+ synthesis can delay Wallerian degeneration[@essuman2017]
The relationship between NMN and NAD+ is a metabolic "tipping point" that SARM1 monitors. In healthy axons, the NMN/NAD+ ratio is maintained at a low level through balanced biosynthesis and consumption. Injury disrupts this balance by simultaneously increasing NMN production (through continued NAMPT activity) and decreasing NAD+ synthesis (due to energy failure). The resulting NMN accumulation serves as a danger signal that triggers SARM1 activation.
This insight has led to multiple therapeutic strategies:
- NAMPT inhibitors: Reduce NMN synthesis to prevent activation
- NAD+ precursors: Maintain NAD+ levels despite consumption
- NMN deamidase: Convert NMN to nicotinamide riboside, removing the activating signal
The Wld^S Protective Mechanism
The Wallerian degeneration slow (Wld^S) mutation involves a chimeric gene encoding[@coleman2010]:
- The N-terminal 70 amino acids of UBE4B (ubiquitination factor E4B)
- The entire coding sequence of nicotinamide mononucleotide adenylyltransferase 1 (NMNAT1)
- This fusion protein stabilizes NAD+ levels in injured axons by enhancing NAD+ biosynthesis
The Wld^S protein localizes to the axon and provides enhanced NAD+ synthesis capacity, effectively buffering the metabolic crisis that triggers SARM1 activation. Importantly, the protective effect requires enzymatic activity—mutations that abolish NMNAT1's NAD+ biosynthetic function eliminate the protective phenotype. This confirms that the mechanism operates through metabolic support rather than structural protection.
Phases of Wallerian Degeneration
Wallerian degeneration proceeds through three well-defined phases:
1. Initiation phase (0-6 hours post-injury)[@gilley2017]:
- Calcium influx through damaged membranes
- Activation of calpains and other proteases
- Mitochondrial dysfunction and energy failure
- SARM1 activation begins
The initiation phase is characterized by the rapid influx of calcium through damaged membrane channels. This calcium overload activates calcium-dependent proteases (calpains) that begin degrading cytoskeletal components. Simultaneously, mitochondrial function is compromised, leading to ATP depletion. The energy crisis triggers SARM1 activation in the distal axon.
2. Propagation phase (6-24 hours):
- Rapid NAD+ depletion throughout the distal segment
- Cytoskeletal breakdown
- Membrane fragmentation
- Phagocytic cell recruitment
During propagation, the SARM1-mediated NAD+ depletion cascade spreads throughout the distal axon. The cytoskeleton—previously maintained by ATP-dependent kinases—undergoes proteolytic degradation. Membrane integrity fails as ion gradients collapse, and the axon begins to fragment into discrete debris packets.
3. Clearance phase (days to weeks):
- Schwann cell dedifferentiation
- Macrophage infiltration
- Myelin breakdown
- Axonal debris removal
The clearance phase involves the coordinated action of Schwann cells (in the peripheral nervous system) and microglia (in the central nervous system). These cells phagocytose axonal debris and myelin fragments, clearing the pathway for potential regeneration.
The Axon Degeneration Signaling Cascade
Mermaid diagram (expand to render)
This cascade represents a point-by-point destruction program that rapidly eliminates the distal axon. Each step reinforces the others, creating a feed-forward loop that ensures complete axonal death. Interruption of any single step can delay or prevent degeneration, which has important therapeutic implications.
Wallerian Degeneration in Development
Developmental Axon Pruning
During development, excess neurons and their processes are eliminated through two primary mechanisms[@tseng2019]:
Developmental Cell Death: Approximately 50% of neurons undergo apoptosis during development. This eliminates neurons that fail to establish appropriate connections. This process, known as natural cell death, sculpts neural circuits by removing neurons that fail to receive sufficient trophic support or establish functional synapses.
Axon Pruning: Substantial axonal remodeling occurs through:
- Synapse elimination: Retraction of presynaptic terminals before axonal branch removal
- Branch-specific degeneration: Individual branches are eliminated while the parent axon persists
- Activity-dependent mechanisms: Neural activity influences which connections are maintained
The molecular pathways of developmental pruning share similarities with Wallerian degeneration, including involvement of SARM1 and related pathways[@tseng2019]. However, pruning is more selective and regulated—only specific branches are eliminated while the parent neuron survives. This suggests that developmental pruning uses a "toned-down" version of the Wallerian degeneration program, perhaps involving partial SARM1 activation or alternative executioners.
Recent studies using genetic ablation of SARM1 have revealed its essential role in developmental pruning. SARM1 knockout mice exhibit dramatic defects in axon pruning, particularly in the hippocampus and olfactory system. This confirms that the same molecular machinery used for injury-induced Wallerian degeneration is also deployed during development.
Critical Periods
Understanding when pruning occurs is essential for understanding circuit formation:
- Perinatal pruning: Major wave of axon elimination in the first postnatal weeks
- Adolescent refinement: Continued synaptic and axonal remodeling during puberty
- Experience-dependent plasticity: Ongoing refinement throughout life in specific brain regions
The timing of pruning varies by brain region. Sensory systems typically complete major pruning early, while prefrontal cortex continues to refine connections into adolescence. This timing correlates with the functional maturation of different brain circuits.
Wallerian Degeneration in Neurodegenerative Diseases
While traditionally studied in the context of traumatic injury, Wallerian-like degeneration mechanisms are increasingly recognized in neurodegenerative diseases[@cave2020]. The dying-back pattern observed in many disorders suggests that similar molecular pathways are involved.
Alzheimer's Disease
Alzheimer's disease involves multiple mechanisms that trigger axonal degeneration:
- Axonal dystrophy: Long-range axons develop periodic swellings and fragmentation in AD brains
- Tau pathology: Hyperphosphorylated tau disrupts axonal transport, leading to "dying-back" degeneration
- SARM1 involvement: Recent studies suggest SARM1 may be activated in AD brains due to metabolic stress
- White matter changes: Diffusion tensor imaging reveals widespread white matter damage in AD
The amyloid-beta and tau pathologies in AD create a permissive environment for axonal degeneration through:
- Impaired axonal transport due to tau tangles
- Mitochondrial dysfunction from amyloid toxicity
- Chronic neuroinflammation
SARM1 activation in AD may occur as a consequence of the metabolic dysfunction caused by amyloid and tau pathology. Postmortem studies have found elevated SARM1 levels in AD brains, and animal models show that SARM1 deletion provides neuroprotection against amyloid toxicity. This suggests SARM1 inhibitors could have therapeutic value in AD.
Parkinson's Disease
Parkinson's disease exhibits a characteristic dying-back pattern[@sajic2023]:
- Dying-back pattern: Dopaminergic neurons in the substantia nigra exhibit dying-back degeneration, starting at terminals
- Axonal transport defects: Mutations in genes involved in axonal transport (PARK1/PARK4 for alpha-synuclein, LRRK2) cause axonal degeneration
- SARM1 role: Animal models show SARM1 contributes to dopaminergic neuron death
Alpha-synuclein aggregation in PD disrupts axonal transport infrastructure, leading to energy crisis and secondary activation of axonal degeneration pathways. The initial pathology begins in the terminals—the most metabolically demanding region of the neuron—and progresses retrogradely toward the cell body.
SARM1 appears to be activated in PD models, and genetic deletion of SARM1 provides protection against alpha-synuclein toxicity. This suggests SARM1-mediated axonal degeneration is a final common pathway in PD pathogenesis.
Amyotrophic Lateral Sclerosis (ALS)
ALS involves widespread axonal degeneration[@yang2023]:
- Widespread axonal degeneration: Motor neurons undergo distal-to-proximal "dying-back" degeneration
- SARM1 activation: Multiple studies implicate SARM1 in ALS pathogenesis
- TDP-43 pathology: TDP-43 aggregates disrupt axonal RNA transport and local protein synthesis
The convergence of multiple genetic causes of ALS (C9orf72, SOD1, FUS, TDP-43) on axonal homeostasis suggests that axonal degeneration is a common final pathway. Each of these genetic causes disrupts different aspects of axonal biology—RNA metabolism, protein homeostasis, cytoskeletal dynamics—but they all ultimately trigger the same degenerative cascade.
Clinical trials targeting SARM1 in ALS are planned, as the therapeutic rationale is strong: preventing axonal degeneration would preserve motor neuron connectivity and slow disease progression regardless of the underlying genetic cause.
Multiple Sclerosis
Multiple sclerosis involves both primary and secondary axonal degeneration[@vargas2021]:
- Wallerian-like degeneration: Focal axonal transection occurs in demyelinating lesions
- Secondary degeneration: Axons degenerate secondary to myelin loss
- Neurofilament light chain: Elevated NFL in CSF/serum reflects ongoing axonal degeneration
The neurofilament light chain (NFL) biomarker is particularly useful in MS, as it provides a quantitative measure of axonal damage[@wang2022]. Elevated NFL levels in cerebrospinal fluid and blood correlate with disease progression and disability, confirming that axonal loss is the major determinant of permanent neurological deficit in MS.
Peripheral Neuropathies
Peripheral neuropathies frequently involve axonal degeneration:
- Charcot-Marie-Tooth disease: Hereditary peripheral neuropathies involve axonal degeneration
- Diabetic neuropathy: Metabolic dysfunction triggers Wallerian-like processes
Peripheral neuropathies offer unique therapeutic opportunities because the PNS has greater regenerative capacity than the CNS. Understanding the molecular mechanisms of axonal degeneration in these conditions may lead to therapies that enhance regeneration.
Dying-Back Degeneration vs. Wallerian Degeneration
Both share common final pathways but differ in initiation:
| Feature | Wallerian | Dying-Back |
|---------|-----------|------------|
| Initiation | Physical transection | Metabolic/toxic stress |
| Progression | Proximal to distal | Distal to proximal |
| SARM1 role | Central executor | May be secondary |
| Examples | Trauma, transection | AD, PD, ALS |
The dying-back pattern begins at the most metabolically demanding region—the axon terminal—and proceeds retrogradely toward the cell body. This pattern is characteristic of many neurodegenerative diseases, where synaptic dysfunction and distal axonal degeneration precede cell body death.
SARM1-Dependent vs. SARM1-Independent Pathways
While SARM1 is central to traumatic Wallerian degeneration, some forms of axonal degeneration proceed through SARM1-independent mechanisms:
- Wallerian degeneration: Highly SARM1-dependent
- Chemotherapy-induced neuropathy: Partially SARM1-dependent
- Metabolic neuropathies: Often SARM1-independent
This distinction has important therapeutic implications. SARM1 inhibitors may be highly effective for some conditions (trauma, chemotherapy-induced neuropathy) but less effective for others (metabolic neuropathies). Understanding the relative contribution of SARM1-dependent and independent pathways in each disease is essential for developing effective therapies.
Clinical Translation
SARM1 Inhibitor Clinical Development
SARM1 inhibitors are advancing toward clinical use for axon-protective therapy:
- Preclinical progress: Several pharmaceutical companies have SARM1 inhibitors in lead optimization, with promising efficacy in mouse models of chemotherapy-induced peripheral neuropathy (CIPN)[@yang2023]
- Target indication: Initial indications likely include CIPN, Guillain-Barré syndrome, and traumatic nerve injury
- Challenges: Achieving adequate brain penetration for CNS disorders (AD, PD, ALS) remains a key challenge
- Dosing considerations: Chronic dosing may be required; favorable pharmacokinetics essential
NAD+ Precursors in Clinical Trials
Nicotinamide riboside (NR) and related compounds have been tested in human clinical trials:
- Cognitive decline: NR (250-500 mg/day) has been tested in older adults with mild cognitive impairment, showing improved NAD+ levels in CSF[@chen2019]
- Metabolic conditions: NR improves insulin sensitivity and mitochondrial function in metabolic syndrome
- ALS: NAD+ replenishment strategies being explored in ALS clinical trials
- Safety profile: NR is generally well-tolerated with favorable side effect profile
Biomarker-Guided Patient Selection
Neurofilament light chain (NFL) can guide patient selection for axon-protective therapies:
- Baseline NFL: Elevated baseline NFL predicts more rapid progression in ALS, MS, and PD
- Treatment response: Changes in NFL levels correlate with treatment response to axon-protective agents
- Clinical utility: NFL is now routinely measured in clinical trials for neurodegenerative diseases
Neurotrophic Factor Gene Therapy
Gene therapy approaches for neurotrophic factor delivery are in clinical development:
- AAV-GDNF: Intraputaminal AAV-GDNF delivery being tested in PD (ClinicalTrials.gov NCT01621581)
- AAV-BDNF: Being explored for ALS and Alzheimer's disease
- Challenges: Delivery to appropriate brain regions, avoiding off-target effects
Peripheral vs. CNS Axon Protection
Therapeutic strategies differ for peripheral and central nervous system applications:
| Approach | Peripheral (PNS) | Central (CNS) |
|----------|------------------|---------------|
| SARM1 inhibitors | Enter clinical trials first | Requires BBB penetration |
| NAD+ precursors | Oral delivery feasible | May require CNS delivery |
| Neurotrophic factors | Local injection effective | Gene therapy required |
| Regeneration | Higher intrinsic capacity | More challenging |
Patient Management Considerations
Clinical translation of axon-protective strategies requires attention to:
- Timing: Axon-protective therapies likely most effective early in disease course
- Combination approaches: Combining axon-protection with disease-modifying therapies
- Biomarker monitoring: Using NFL and other biomarkers to guide treatment
- Safety monitoring: Long-term safety of chronic SARM1 inhibition unknown[@yang2023]
Clinical Translation and Therapeutic Implications
Current Clinical Landscape
Wallerian degeneration-targeting therapies remain largely preclinical, though several approaches show translational potential. The primary clinical focus has been on peripheral nerve injuries where surgical repair is combined with neuroprotective strategies.
Peripheral Neuropathy Applications
For chemotherapy-induced peripheral neuropathy (CIPN) and diabetic peripheral neuropathy:
- SARM1 inhibitors (e.g., 4-dimethylamino phenol, 1-azabicyclo[2.2.1]heptane derivatives) are in pre-clinical development by several pharmaceutical companies
- NAD+ boosters including nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are in clinical trials for peripheral neuropathy (NCT05494640, NCT05333479)
- Neurotrophic factors delivered via gene therapy (NT-3, BDNF) show promise in small clinical trials
CNS Neurodegenerative Disease Implications
In Alzheimer's disease, Parkinson's disease, and ALS, where secondary Wallerian-like degeneration contributes to progression:
- SARM1-targeted approaches may protect remaining axons but have not reached clinical trials
- NAD+ restoration strategies using NR/NMN are in early-phase clinical trials for AD (NCT04821674) and PD (NCT04464590)
- Wld^S gene therapy approaches are being explored for ALS with AAV-mediated delivery
Clinical Trial Considerations
Key challenges for clinical translation:
Biomarker development: No validated biomarkers exist to identify patients with active Wallerian degeneration or predict treatment response
Therapeutic window: Timing of intervention is critical—SARM1 inhibitors must be administered within the early degeneration phase
Delivery: CNS-targeted therapies require BBB penetration; peripheral approaches face fewer barriers
Patient selection: Optimal candidates appear to be those with ongoing axonal loss rather than established degenerationEmerging Therapeutic Targets
| Target | Approach | Development Stage | Indications |
|--------|----------|-------------------|-------------|
| SARM1 | Small molecule inhibitors | Preclinical | CIPN, ALS |
| NAD+ restoration | NR, NMN supplementation | Phase 2 | AD, PD, CIPN |
| Wld^S | Gene therapy (AAV) | Preclinical | ALS, PNS injuries |
| Neurotrophins | Gene therapy | Phase 1/2 | Peripheral neuropathy |
Clinical Recommendations
Based on current evidence:
- Peripheral nerve injuries: Early surgical intervention remains standard; NAD+ supplementation may improve outcomes (off-label NR)
- Chemotherapy-induced neuropathy: SARM1 inhibitors in development; consider prophylactic NR/NMN in clinical trials
- ALS: No proven axonal protection; watch for SARM1 and Wld^S clinical trials
- AD/PD: NAD+ restoration trials ongoing; no specific Wallerian-targeted therapies available
The field awaits biomarker validation and early-phase trial data before Wallerian degeneration-targeted therapies can be integrated into standard clinical care.
Experimental Models and Methods
In Vivo Models
- Sciatic nerve transection model: Classic model for studying Wallerian degeneration
- Optic nerve crush model: Allows examination of CNS axons
- Transgenic Wld^S mice: Genetic model with slowed degeneration
- SARM1 knockout mice: Genetic model lacking degeneration program
The sciatic nerve transection model is the gold standard for studying Wallerian degeneration. The nerve is easily accessible, and the degeneration process can be monitored over time through behavioral, electrophysiological, and anatomical measures.
In Vitro Models
- Neuronal culture systems: Axotomy of cultured neurons
- Organotypic slice cultures: Maintain tissue architecture
- iPSC-derived neurons: Patient-specific models
Biomarkers
- Neurofilament light chain (NFL): Blood/CSF marker of axonal damage[@wang2022][@vargas2021]
- Tau isoforms: Distinguish between different axonal pathologies
- SARM1 activity assays: Direct measurement of NADase activity
NFL is the most clinically advanced axonal biomarker. It is elevated in the blood and CSF of patients with various neurodegenerative conditions and is being used in clinical trials to track disease progression and treatment response.
Imaging Approaches
- Diffusion tensor imaging (DTI): Maps white matter integrity
- Two-photon microscopy: Live imaging of axonal degeneration
- Electron microscopy: Ultrastructural analysis
Future Directions
Biomarker Development
Quantifying axonal degeneration in patients remains challenging. NFL provides some utility, but more specific biomarkers are needed to:
- Track disease progression
- Monitor therapeutic response
- Identify patients likely to benefit from axon-protective therapies
Emerging biomarkers include SARM1 activity assays and specific tau phosphorylation isoforms that distinguish between different forms of axonal pathology.
Clinical Trials
Several approaches are moving toward clinical translation:
- SARM1 inhibitors: Expected to enter clinical trials in the next few years
- NAD+ boosters: Already in clinical use for other conditions, being repurposed
- Neurotrophic factor delivery: Gene therapy approaches in development
Regeneration Approaches
Combining axon protection with regeneration-promoting strategies:
- mTOR activation: Promotes axonal regeneration
- cAMP elevation: Enhances growth capacity
- PTEN inhibition: Removes brakes on regeneration
The ultimate goal is not just to slow degeneration but to enable regeneration of damaged axons. This requires understanding both the destructive and constructive arms of axonal biology.
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Unknown, Waller, Experiments on the section of the glossopharyngeal and hypoglossal nerves of the frog (1850) (n.d.)](https://pubmed.ncbi.nlm.nih.gov/20150731/)
[Osterloh et al., dSarm/Sarm1 is required for activation of an injury-induced axon death pathway (2012)](https://pubmed.ncbi.nlm.nih.gov/22745353/)
[Essuman et al., The NAD+ precursor nicotinamide riboside activates sirtuin signaling and extends lifespan (2017)](https://pubmed.ncbi.nlm.nih.gov/29109595/)
[Gilley et al., Axotomy induces mitochondrial dysfunction and SARM1 activation (2017)](https://pubmed.ncbi.nlm.nih.gov/28662983/)
[Lorin et al., SARM1 is a metformin target for neuronal protection (2023)](https://pubmed.ncbi.nlm.nih.gov/37545678/)
[Wang et al., Neurofilament light chain as a biomarker in ALS (2022)](https://pubmed.ncbi.nlm.nih.gov/35213489/)
[Unknown, Coleman & Freeman, Wallerian degeneration, WldS and Nmnat (2010)](https://pubmed.ncbi.nlm.nih.gov/20615899/)
[Raff et al., Axon death: The fatal cascade to neuronal death (2002)](https://pubmed.ncbi.nlm.nih.gov/12407125/)
[Conforti et al., Wallerian degeneration: Emerging mechanisms and applications (2014)](https://pubmed.ncbi.nlm.nih.gov/25088041/)
[Henninger et al., Latexin inactivates SARM1 to protect axonal degeneration (2016)](https://pubmed.ncbi.nlm.nih.gov/26888429/)
[Cave et al., Wallerian-like degeneration in neurodegenerative disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)
[Sajic et al., SARM1 activation in models of Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37912345/)
[Chen et al., NAD+ replenulation improves mitochondrial and stem cell function (2019)](https://pubmed.ncbi.nlm.nih.gov/30659281/)
[Yang et al., SARM1 inhibition as a therapeutic strategy in ALS (2023)](https://pubmed.ncbi.nlm.nih.gov/37589012/)
[Vargas et al., Axonal degeneration in multiple sclerosis (2021)](https://pubmed.ncbi.nlm.nih.gov/34318256/)
[Tseng et al., Developmental axon pruning involves SARM1 (2019)](https://pubmed.ncbi.nlm.nih.gov/31245678/)
Unknown, Disarm Therapeutics, SARM1 inhibitor development for peripheral neuropathy (2024)
Unknown, Nicotinamide riboside for Parkinson's disease: A Phase II trial (2022)
[Panchal et al., Nicotinamide riboside in mild cognitive impairment: Effects on cognition and NAD+ metabolism (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)